Qi Lin Selected Research

cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)

1/2022	URB597 and Andrographolide Improve Brain Microvascular Endothelial Cell Permeability and Apoptosis by Reducing Oxidative Stress and Inflammation Associated with Activation of Nrf2 Signaling in Oxygen-Glucose Deprivation.
2/2021	Preservation of spatial memory and neuroprotection by the fatty acid amide hydrolase inhibitor URB597 in a rat model of vascular dementia.
1/2021	Neuroprotective Effects of VEGF-A Nanofiber Membrane and FAAH Inhibitor URB597 Against Oxygen-Glucose Deprivation-Induced Ischemic Neuronal Injury.
12/2019	URB597 protects against NLRP3 inflammasome activation by inhibiting autophagy dysfunction in a rat model of chronic cerebral hypoperfusion.
12/2017	Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 ameliorate neuroinflammatory responses in chronic cerebral hypoperfusion model by blocking NF-κB pathways.
1/2017	URB597 improves cognitive impairment induced by chronic cerebral hypoperfusion by inhibiting mTOR-dependent autophagy.
10/2016	Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 may protect against cognitive impairment in rats of chronic cerebral hypoperfusion via PI3K/AKT signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Qi Lin Research Topics

Disease

29	Neoplasms (Cancer) 04/2022 - 09/2005
20	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2014
15	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 10/2014
7	Breast Neoplasms (Breast Cancer) 03/2022 - 09/2013
6	Cognitive Dysfunction 02/2021 - 06/2010
5	Glioma (Gliomas) 07/2015 - 07/2007
3	Carcinoma (Carcinomatosis) 04/2022 - 09/2005
3	Edema (Dropsy) 03/2022 - 10/2008
3	Inflammation (Inflammations) 01/2022 - 01/2018
3	Infections 05/2021 - 11/2010
3	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 01/2008
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020 - 09/2016
3	Neuroinflammatory Diseases 12/2019 - 12/2017
3	Fistula 12/2009 - 10/2003
2	Corneal Opacity 01/2022 - 10/2018
2	Virus Diseases (Viral Diseases) 01/2022 - 09/2013
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2022 - 01/2021
2	Migraine Disorders (Migraine) 09/2021 - 01/2020
2	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 02/2021 - 01/2018
2	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 01/2020
2	Brain Ischemia (Cerebral Ischemia) 01/2021 - 10/2009
2	Brain Edema (Cerebral Edema) 11/2020 - 07/2004
2	Pancreatitis 10/2020 - 03/2020
2	Necrosis 03/2020 - 09/2013
2	Carcinogenesis 01/2020 - 01/2019
2	Hypertension (High Blood Pressure) 01/2020 - 04/2014
2	Wounds and Injuries (Trauma) 01/2020 - 04/2009
2	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2020
2	Lymphatic Metastasis 01/2019 - 01/2019
2	Medulloblastoma 10/2018 - 07/2015
2	Neurodegenerative Diseases (Neurodegenerative Disease) 09/2013 - 02/2011
2	Prolapse 05/2012 - 10/2008
2	Epistaxis (Nosebleed) 05/2012 - 10/2008
2	Lacrimal Duct Obstruction 08/2011 - 10/2008
1	Cysts 09/2022
1	Granulomatous Mastitis 09/2022
1	Patent Ductus Arteriosus 05/2022
1	Rectal Neoplasms (Rectal Cancer) 03/2022
1	Chronic Obstructive Pulmonary Disease (COPD) 03/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 03/2022
1	Triple Negative Breast Neoplasms 03/2022
1	Diabetes Mellitus 02/2022

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2003
7	Biomarkers (Surrogate Marker)IBA 04/2022 - 12/2012
7	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 01/2022 - 10/2016
5	RNA (Ribonucleic Acid)IBA 03/2022 - 01/2017
4	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 10/2009
4	Oxygen (Dioxygen)IBA 01/2022 - 09/2007
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 10/2003
4	Neuroprotective AgentsIBA 01/2021 - 10/2009
4	Biological ProductsIBA 12/2020 - 11/2010
4	Messenger RNA (mRNA)IBA 11/2019 - 10/2003
4	panaxydolIBA 04/2009 - 07/2007
3	Small Interfering RNA (siRNA)IBA 03/2022 - 12/2014
3	Therapeutic UsesIBA 09/2021 - 10/2008
3	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 02/2021 - 10/2016
3	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2021 - 10/2019
3	Pharmaceutical PreparationsIBA 01/2021 - 10/2018
3	Indicators and Reagents (Reagents)IBA 01/2020 - 01/2015
3	Cannabinoid Receptor AgonistsIBA 01/2018 - 10/2016
3	Cetuximab (Erbitux)FDA Link 01/2018 - 03/2016
2	Hemoglobins (Hemoglobin)IBA 04/2022 - 01/2020
2	Phosphotransferases (Kinase)IBA 03/2022 - 01/2017
2	andrographolideIBA 01/2022 - 10/2019
2	Circular RNAIBA 01/2022 - 01/2020
2	Complementary DNA (cDNA)IBA 05/2021 - 10/2020
2	LipidsIBA 01/2021 - 01/2019
2	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2021 - 01/2019
2	Fluorescein (Funduscein)FDA LinkGeneric 07/2020 - 08/2011
2	SolutionsIBA 01/2020 - 09/2007
2	AntigensIBA 01/2020 - 01/2020
2	Tumor Biomarkers (Tumor Markers)IBA 01/2020 - 01/2020
2	CarbohydratesIBA 01/2020 - 01/2020
2	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 01/2018
2	Sphingosine-1-Phosphate ReceptorsIBA 01/2019 - 10/2014
2	Iodine-125IBA 01/2019 - 01/2017
2	Protein AggregatesIBA 09/2013 - 02/2011
2	SiliconesIBA 05/2012 - 10/2008
1	Immunoglobulin M (IgM)IBA 09/2022
1	AlbuminsIBA 04/2022
1	human ERBB2 proteinIBA 03/2022
1	Phenobarbital (Luminal)FDA Link 03/2022
1	SmokeIBA 03/2022
1	Blood Glucose (Blood Sugar)IBA 02/2022

Therapy/Procedure

11	Therapeutics 05/2022 - 03/2016
6	Drug Therapy (Chemotherapy) 01/2022 - 12/2012
3	Percutaneous Collagen Induction 12/2021 - 11/2020
3	Ligation 01/2019 - 09/2007
3	Neoadjuvant Therapy 04/2016 - 09/2013
2	Segmental Mastectomy (Lumpectomy) 03/2022 - 09/2013
2	Penetrating Keratoplasty 01/2022 - 10/2018
2	Aftercare (After-Treatment) 09/2021 - 09/2013
2	Cardiopulmonary Resuscitation (CPR) 04/2021 - 11/2020
2	Microbubbles 11/2020 - 01/2019
2	Transplantation 11/2020 - 08/2006
2	Brachytherapy 01/2019 - 01/2017
2	Length of Stay 10/2014 - 04/2012
1	Nephroureterectomy 04/2022
1	Mastectomy (Mammectomy) 03/2022
1	Critical Care (Surgical Intensive Care) 02/2022